Abstract: A fluidic system for producing extracellular vesicles from producer cells, including at least one container, a liquid medium contained by the container and producer cells, characterised in that it also includes microcarriers suspended in the liquid medium, the majority of producer cells being adherent to the surface of the microcarriers, and a liquid medium agitator, the agitator and the dimensions of the container being adapted to control a turbulent flow of the liquid medium in the container.

Abstract: A fluidic system for producing extracellular vesicles from producer cells, including at least one container, a liquid medium contained by the container and producer cells, characterised in that it also includes microcarriers suspended in the liquid medium, the majority of producer cells being adherent to the surface of the microcarriers, and a liquid medium agitator, the agitator and the dimensions of the container being adapted to control a turbulent flow of the liquid medium in the container.

Abstract: Several gastrointestinal and gynecological malignancies have the potential to disseminate and grow in the peritoneal cavity. The occurrence of peritoneal carcinomatosis (PC) has been shown to significantly decrease overall survival in patients. Treatment of residual microscopic disease remains a challenge with new anticancer modalities development. Now, the inventors propose an innovative therapeutic management of peritoneal carcinomatosis (PC) that is bio-inspired and tumor-targeted by engineering MSC-derived EVs to encapsulate a photosensitizer (mTHPC) for improved photodynamic therapy efficiency and safety. In this work, the inventors first evaluated the biodistribution of EVs-mTHPC in a murine PC model and highlighted superior accumulation of mTHPC in the tumor compared to other mTHPC formulations (free drug and liposomal one (Foslip®). The effectiveness of PDT mediated by mTHPC vectorized in EVs has then been evaluated in PC.

Abstract: The present invention relates to a composition comprising at least one poloxamer compound for use in the treatment of a fistula in an individual.

Abstract: A fluidic system for loading a therapeutic or imaging agent into the lumen of extracellular vesicles from producer cells, including at least one container, a liquid medium contained in the container, producer cells, a liquid medium stirrer and a device for controlling the speed of the stirrer suitable for the growth of the producer cells, wherein it also includes a device for controlling the speed of the stirrer and the stirrer, of which the shape and dimensions of the container are suitable for generating a turbulent flow of the liquid medium in the container for exerting shear stresses on the producer cells in order to carry out the loading of a therapeutic or imaging agent into the lumen of the extracellular vesicles produced simultaneously by the fluidic system.

Abstract: A fluidic system for producing extracellular vesicles from suspended producer cells, including at least one container, a liquid medium contained in the container, suspended producer cells, a liquid medium agitator, a device for controlling the speed of the agitator suitable for the growth of the suspended producer cells, wherein the device for controlling the speed of the agitator, the agitator and the shape and dimensions of the container are suitable for generating a turbulent flow of the liquid medium in the container for exerting shear stresses on the producer cells in order to carry out the production of extracellular vesicles, the Kolmogorov length of the flow being less than or equal to 50 ?m.

Abstract: A fluidic system for producing extracellular vesicles from producer cells, including at least one container, a liquid medium contained by the container and producer cells, characterised in that it also includes microcarriers suspended in the liquid medium, the majority of producer cells being adherent to the surface of the microcarriers, and a liquid medium agitator, the agitator and the dimensions of the container being adapted to control a turbulent flow of the liquid medium in the container.

Abstract: The present invention relates to a composition comprising at least one poloxamer compound for use in the treatment of a fistula in an individual.

Abstract: The invention relates to a process which enables optimal aggregation of cells, typically of stem cells, promoting the organisation thereof and advantageously the differentiation thereof, in particular in the context of the formation of a tissue substitute. This process comprises exposing pretreated cells to a magnetic field and makes it possible to obtain large cell aggregates, even prepared in the absence of support matrix and/or of growth factor. The invention also relates to the cell aggregates that can be obtained using such a process and also to the uses thereof as tissue initiators with a view to obtaining a tissue structure of interest in vitro, ex vivo or in vivo. Moreover, it relates to the resulting tissue structures and to the uses thereof in research or in therapy as tissue substitutes. The present application also provides a method which advantageously makes it possible to monitor the development of the tissue of interest in vivo.